Pearson T C, Alexander D Z, Hendrix R, Elwood E T, Linsley P S, Winn K J, Larsen C P
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Transplantation. 1996 Apr 15;61(7):997-1004. doi: 10.1097/00007890-199604150-00002.
Allograft rejection is dependent on T cell activation, which requires both the engagement of the T cell receptor by antigen in the context of the MHC molecules and costimulatory signals delivered by cell surface molecules such as B7-CD28/CTLA4 pathway. CTLA4-Ig is a fusion protein that blocks this pathway and has previously been shown to prolong both allograft and xenograft survival. The current study demonstrates markedly prolonged murine cardiac allograft survival and specific prolongation of secondary skin grafts using a combination of CTLA4-Ig plus donor bone marrow. A role for hematopoietic chimerism in the establishment of CTLA4-Ig-induced transplantation tolerance was investigated using reverse transcriptase polymerase chain reaction analysis of recipient tissues. Expression of donor-specific MHC class II transcripts in both peripheral and lymphoid tissues was demonstrated at greater than 200 days after transplant. To investigate the functional significance of this observation, heart donors, and donor bone marrow were irradiated before transplantation in CTLA4-Ig-treated recipients. A reduction in allograft survival was associated with irradiation of both the donor heart and the bone marrow. These results suggest that there may be a donor-derived radiosensitive element that enhances allograft survival in this model. Reverse transcriptase polymerase chain reaction analysis of allografts of tolerant and control animals at days 5, 8, and 12 after transplantation failed to demonstrate a dramatic difference in the expression of interleukin (IL)-2, IL-4, IL-10, and interferon-gamma message. Cytotoxicity effector transcripts were largely intact in CTLA4-Ig + bone marrow-treated recipients as they showed no decrease in intragraft granzyme, perforin, Fas, or Fas ligand transcripts during thr first 8 days after transplant. These results imply that complex mechanisms may be important for the induction and maintenance of transplantation tolerance in the CTLA4-Ig plus bone marrow murine cardiac allograft model.
同种异体移植排斥反应依赖于T细胞活化,这既需要在MHC分子背景下抗原与T细胞受体结合,也需要细胞表面分子传递的共刺激信号,如B7 - CD28/CTLA4途径。CTLA4 - Ig是一种融合蛋白,可阻断该途径,此前已证明它能延长同种异体移植和异种移植的存活时间。当前研究表明,联合使用CTLA4 - Ig和供体骨髓可显著延长小鼠心脏同种异体移植的存活时间,并特异性延长二次皮肤移植的存活时间。利用逆转录酶聚合酶链反应分析受体组织,研究了造血嵌合体在建立CTLA4 - Ig诱导的移植耐受中的作用。移植后200多天,在外周组织和淋巴组织中均检测到供体特异性MHC II类转录本的表达。为了研究这一观察结果的功能意义,在接受CTLA4 - Ig治疗的受体中,对心脏供体和供体骨髓在移植前进行照射。供体心脏和骨髓的照射均导致同种异体移植存活时间缩短。这些结果表明,在该模型中可能存在一种供体来源的放射敏感元件,可增强同种异体移植的存活。对移植后第5、8和12天的耐受动物和对照动物的同种异体移植进行逆转录酶聚合酶链反应分析,未发现白细胞介素(IL)-2、IL - 4、IL - 10和干扰素 - γ信息表达有显著差异。在接受CTLA4 - Ig + 骨髓治疗的受体中,细胞毒性效应转录本基本完整,因为在移植后的前8天内,移植组织内颗粒酶、穿孔素、Fas或Fas配体转录本均未减少。这些结果表明,复杂的机制可能对CTLA4 - Ig加骨髓小鼠心脏同种异体移植模型中移植耐受的诱导和维持很重要。